Abstract 5303: FAIMS technology in urinary volatile organic compound analysis to detect colorectal cancer
Authors: Christopher Psutka, Marina Yamada, Akihisa Matsuda, Kazuya Yamahatsu, Satoshi Matsumoto, Toshihiko Kitayama, Nobuo Nakano, Jyunichi Koyano, Tohru Mikoshiba, Masao Miyashita
Journal: Cancer Research (2017)

Abstract Introduction This is an investigation of the capability of FAIMS (Field Asymmetric Ion Mobility Spectrometry) technology as a tool for non-invasive detection of Colorectal Cancer (CRC) through urinary volatile organic compound analysis. It expands on "Detection of Colorectal Cancer (CRC) by Urinary Volatile Organic Compound Analysis" (Ramesh P. Arasaradnam et al, 2014) with an increased sample population and local to Japan, also comparing in-house data of CA19-9 and carcinoembryonic antigen (CEA) markers. Experiment Conducted at Nippon Medical School Chiba Hokusoh Hospital, urine samples were collected and frozen at -80°C from 139 patients at various stages of CRC and 78 healthy control samples. The samples were thawed in batches and placed in ice hours prior to testing. 2 ml of each urine sample was aliquoted into 10 ml vials for processing with the commercial FAIMS device (Lonestar, Owlstone, UK). Each vial was heated in the device to 40°C to create headspace with sufficient VOCs then a carrier gas (clean dry air) delivered the headspace (0.5 L/min) diluted with a make-up flow (2 L/min). The FAIMS device was set to scan at 0 to 100% electric dispersion field in 51 steps and compensation voltage between -6 V and +6 V in 512 steps, producing data matrices for each sample's analysis. Principal Component Analysis (PCA) followed by Partial Least Squares Discriminant Analysis (PLS-DA) of each sample was conducted using SIMCA 13 (Umetrics, Sweden). See Table Conclusions FAIMS technology achieved a high rate of separation between the CRC and healthy control urine samples with 64.7% sensitivity and 82.1% specificity overall. As the CRC stage advances the sensitivity increased from 27.3% to 100%. Results show excellent potential to use FAIMS technology as an early screening tool for CRC, particularly impressive compared to in-house sensitivity data of CA19-9 and CEA markers. Further research into FAIMS screening of other cancer types through VOC biomarker analysis of urine, breath, and feces is recommended. &amp;gt;Detection ResultsCRC STAGEFAIMSOTHER MARKERSCA19-9CEATrue PositiveFalse NegativeSensitivityFalse PositiveTrue NegativeSpecificityNo. of SamplesSensitivitySensitivityI123227.3%146482.1%434.7%18.6%II181260.0%146482.1%3116.1%32.3%III45590.0%146482.1%5219.2%36.5%IV150100%146482.1%1735.3%64.7%ALL904964.7%146482.1%14316.1%33.6% Citation Format: Christopher Psutka, Marina Yamada, Akihisa Matsuda, Kazuya Yamahatsu, Satoshi Matsumoto, Toshihiko Kitayama, Nobuo Nakano, Jyunichi Koyano, Tohru Mikoshiba, Masao Miyashita. FAIMS technology in urinary volatile organic compound analysis to detect colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5303. doi:10.1158/1538-7445.AM2017-5303